Head-to-head · WeighScore
Framework vs Mevo Health
The verdict
Framework takes it — 65.1/100 to 60.2/100.
Framework grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Framework is a personalized-plan GLP-1 telehealth platform offering compounded semaglutide and tirzepatide with doctor-guided treatment selection.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Framework | Mevo Health |
|---|---|---|
| WeighScore | 65.1/100 | 60.2/100 |
| Grade | C | C |
| Scorecard rank | #230 | #327 |
| Semaglutide | $100/mo (starting dose, compounded) | $199/mo (all doses, compounded) |
| Tirzepatide | $100/mo (starting dose, compounded) | $259/mo (all doses, compounded) |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Yes |
Graded #230 · C
Strengths
- Named 503B pharmacy partner (The Pharmacy Hub) disclosed — the FDA-registered outsourcing-facility pathway, distinct from 503A
- Publishes the FDA compounded-medication disclaimer
- $25/week pricing (~$100/mo) is among the most aggressive in the directory
- $0 membership fees
- Phone support published, toll-free (888) 412-0666
Where it loses points
- LegitScript ID / certification not shown on the homepage
- States-served list not disclosed
- Medical director / clinical leadership not disclosed
- Corporate legal entity not disclosed (no footer copyright)
- Governing law / arbitration venue not stated
Graded #327 · C
Strengths
- LegitScript verification badge on multiple pages
- Publishes the FDA compounded-medication disclaimer
- Four named board-certified physicians disclosed (Wasef, Suppa, Sakla, Chikando)
- Both semaglutide and tirzepatide in injection and oral-tablet forms — rare in DTC
- Public entry-level pricing surfaced
Where it loses points
- States served not listed on any public page
- Pharmacy partners not named (only '503A U.S. compounding pharmacies' with unlabeled logos)
- No formal Medical Director role disclosed
- Only 'as low as' entry pricing shown — no per-dose itemization
- No SOC 2 certification claimed
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.